Skip to Main Content

Paper Details

CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma.
J Immunother Cancer
175
2019
B2M, CAR, CAR T cells, CAR T-cell, CRISPR, Cas9, EGFRvIII CAR, PD-, PD-1, PDCD1, T, T-cell, TRAC, Triple gene-edited CAR T cells, allogeneic, beta-2 microglobulin, cancers, endogenous T-cell receptor, glioblastoma, glioma, gliomas, hematological malignancies, human, intracranial tumors, mice, programmed cell death ligand 1, solid tumors, universal, universal EGFRvIII CAR T cells
Author NameAffiliation
Henia Darr
Bob S CarterMassachusetts General Hospital and Harvard Medical School
  • 1 - 2

Datasets

Release 1.2